Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

January 25, 2007 09:01 ET

Holmes Biopharma-Clinical Research Showing Strong Growth

SCOTTSDALE, ARIZONA--(CCNMatthews - Jan. 25, 2007) - Holmes Biopharma, Inc. (OTCBB:HLMB) announces that sales for its Qualia Phase 1 operation in Omaha, Nebraska continue to show very strong growth.

"In 2006, Qualia successfully completed seven clinical projects and we have already received requests for several follow-up projects from the same sponsors. Furthermore, we are on schedule to initiate at least four additional new projects in January and anticipate reaching the $2 Million milestone in signed contracts by the end of February 2007," stated Dr. Sohail Khattak, President and CEO of Qualia.

"Business development activity continues to grow and request for proposals (RFP's) are being received and responded to weekly," added John Metcalfe, President.

About Holmes:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. It currently has clinics in Omaha, Nebraska and Toronto, Canada. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information